India Healthtech's Broken Promise: The Category That Never Figured Out Distribution
India has 1.4 billion patients and a $371B healthcare market. Healthtech startups have raised $3B+. None of them have solved the actual problem.
Get 1 unfair insight every week from India's startup ecosystem.
Read by serious founders and investors. No fluff.
“India's healthcare distribution problem is not a technology problem. It is a trust problem layered on top of an incentive problem layered on top of a fragmentation problem. Every healthtech startup that approached it as a technology problem failed to scale past urban Tier-1 cities.”
“The healthtech companies that are actually growing in India — 1mg, Practo, Apollo 24/7 — are all doing some version of the same thing: using digital as an acquisition layer but physical infrastructure as the actual delivery mechanism. The 'pure digital' healthtech model has not produced a single scaled business.”
“The next wave of Indian healthtech funding will go to companies that own the last mile: diagnostics logistics, pharmacy fulfillment at the neighborhood level, and health worker enablement tools that extend a doctor's reach without replacing the doctor. The category that skips the last mile will keep hitting the same distribution ceiling.”
Continue reading with Blog Pass
This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.
Most founders reading this won't act on it.
The ones who will, get our next insight first.
Amit Tyagi
Founder, AletheiaAI & GP, Fitoor Capital
Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.
Run a fundability check
AletheiaAI reads your deck the way a healthcare investor does — asking whether your distribution model works outside Bangalore and Mumbai.
Don’t miss the next one
One insight every week. No fluff.
Sector theses, product teardowns, founder lessons, and Indian unicorn deconstructions. Read by founders preparing to raise and investors building conviction.
One contrarian insight. Every week. No generic startup advice.
Join founders and investors building with better information.